Multi-centre, Randomized, Double-blind, Parallel-group Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Once Daily Compared With Vilanterol (VI) Inhalation Powder Once Daily on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

Multi-centre, Randomized, Double-blind, Parallel-group Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Once Daily Compared With Vilanterol (VI) Inhalation Powder Once Daily on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Vilanterol/fluticasone furoate (Primary) ; Vilanterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 09 Apr 2018 This trial has been completed in Spain, according to European Clinical Trials Database
    • 01 Mar 2018 Planned End Date changed from 21 Mar 2018 to 23 Apr 2018.
    • 01 Mar 2018 Planned primary completion date changed from 14 Apr 2018 to 23 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top